{"id":"acamprosate-campral","safety":{"commonSideEffects":[{"rate":"17","effect":"Diarrhea"},{"rate":"13","effect":"Headache"},{"rate":"8","effect":"Nausea"},{"rate":"7","effect":"Asthenia/weakness"},{"rate":"6","effect":"Anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acamprosate is believed to act as a weak antagonist at NMDA receptors and may enhance GABA-mediated inhibitory neurotransmission, helping to normalize the hyperexcitable state of the central nervous system that develops during alcohol dependence. By restoring glutamate-GABA balance, it reduces cravings and protects against relapse in alcohol-dependent patients who have achieved abstinence.","oneSentence":"Acamprosate modulates glutamate and GABA neurotransmission to restore neurochemical balance disrupted by chronic alcohol use.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:18.639Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance of abstinence in alcohol-dependent patients"}]},"trialDetails":[{"nctId":"NCT07204977","phase":"PHASE1","title":"Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2026-02-02","conditions":"Amyotrophic Lateral Sclerosis, Motor Neuron Disease","enrollment":30},{"nctId":"NCT06269627","phase":"PHASE4","title":"Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder","status":"RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2025-05-07","conditions":"Alcohol Use Disorder","enrollment":48},{"nctId":"NCT07060638","phase":"PHASE2","title":"Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial","status":"RECRUITING","sponsor":"Samer Gawrieh","startDate":"2026-01-27","conditions":"Alcohol-associated Hepatitis","enrollment":216},{"nctId":"NCT06303778","phase":"NA","title":"Combining a Smartphone App With Medications to Manage Heavy Drinking","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-11-01","conditions":"Alcohol Use Disorder (AUD)","enrollment":330},{"nctId":"NCT03818191","phase":"PHASE4","title":"Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-07-15","conditions":"Alcohol Use Disorder","enrollment":288},{"nctId":"NCT06312800","phase":"PHASE2","title":"Acamprosate and Methazolamide for Essential Tremor","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2016-03","conditions":"Essential Tremor","enrollment":""},{"nctId":"NCT06471686","phase":"PHASE2","title":"Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2021-12-01","conditions":"Alcohol Use Disorder, Liver Transplant; Complications","enrollment":30},{"nctId":"NCT03634917","phase":"PHASE3","title":"Investigation of the Efficacy of Acamprosate and Calcium in Comparison to Placebo as Validation of a Behavioural Test for Alcohol Dependence","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2020-08-05","conditions":"Alcoholism","enrollment":82},{"nctId":"NCT00655967","phase":"PHASE4","title":"Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2006-12","conditions":"Alcohol Dependence","enrollment":""},{"nctId":"NCT04287920","phase":"PHASE2","title":"Acamprosate Safe to Use in Individuals With Liver Disease.","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-09-21","conditions":"Alcohol-related Liver Disease","enrollment":12},{"nctId":"NCT04287790","phase":"","title":"Promoting Medications for Alcohol Use Disorder on the General Medicine Service","status":"TERMINATED","sponsor":"Yale University","startDate":"2020-01-01","conditions":"Alcohol Use Disorder","enrollment":67},{"nctId":"NCT02998151","phase":"EARLY_PHASE1","title":"Neurophysiological and Acute Pharmacological Studies in FXS Patients","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2016-01","conditions":"Fragile X Syndrome","enrollment":29},{"nctId":"NCT02064010","phase":"PHASE2","title":"A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia","status":"WITHDRAWN","sponsor":"Synchroneuron Inc.","startDate":"2014-02","conditions":"Drug-induced Tardive Dyskinesia","enrollment":""},{"nctId":"NCT02217007","phase":"PHASE2","title":"A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome","status":"WITHDRAWN","sponsor":"Synchroneuron Inc.","startDate":"2015-04","conditions":"Tourette Syndrome","enrollment":""},{"nctId":"NCT01813318","phase":"PHASE1","title":"Study of Acamprosate in Autism","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2013-07-02","conditions":"Autistic Disorder","enrollment":36},{"nctId":"NCT01911455","phase":"PHASE1","title":"Study of Acamprosate in Fragile x Syndrome","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2013-08-27","conditions":"Fragile X Syndrome","enrollment":46},{"nctId":"NCT04498897","phase":"PHASE2","title":"Vortioxetine for Treatment of Depressive Mood and Alcohol Use","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2019-01-25","conditions":"Depressive Disorder, Major, Alcoholism","enrollment":128},{"nctId":"NCT00385268","phase":"PHASE2","title":"Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2006-11","conditions":"Cocaine Dependence","enrollment":60},{"nctId":"NCT00463346","phase":"PHASE3","title":"Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-09","conditions":"Alcohol Dependence, Schizophrenia","enrollment":23},{"nctId":"NCT00688324","phase":"PHASE4","title":"Biomarker Study of Acamprosate in Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2008-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":36},{"nctId":"NCT01300923","phase":"PHASE2","title":"Acamprosate in Youth With Fragile X Syndrome","status":"COMPLETED","sponsor":"Indiana University","startDate":"2010-08","conditions":"Fragile X Syndrome, Autism Spectrum Disorders","enrollment":14},{"nctId":"NCT00466661","phase":"PHASE4","title":"Acamprosate vs. Placebo in Bipolar Alcoholics","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2007-04","conditions":"Alcohol Dependence, Bipolar Disorder","enrollment":33},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT02107352","phase":"","title":"Effect of Anti-craving Medication on Cognitive Functions in Alcohol Dependence: an ERP Study","status":"COMPLETED","sponsor":"Brugmann University Hospital","startDate":"2013-12-01","conditions":"Alcohol Dependence","enrollment":80},{"nctId":"NCT00571103","phase":"PHASE4","title":"Acamprosate in the Treatment of Pathological Gambling","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2007-10","conditions":"Pathological Gambling","enrollment":26},{"nctId":"NCT00381043","phase":"PHASE4","title":"Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2006-08","conditions":"Alcohol Dependence","enrollment":100},{"nctId":"NCT00656630","phase":"PHASE2","title":"Medication Development in Alcoholism: Acamprosate Versus Naltrexone","status":"COMPLETED","sponsor":"The Scripps Research Institute","startDate":"2007-12","conditions":"Alcoholism","enrollment":68},{"nctId":"NCT00571922","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2007-07","conditions":"Methamphetamine Dependence, Treatment Seeking","enrollment":72},{"nctId":"NCT00360594","phase":"PHASE2","title":"Acamprosate Initiated During Alcohol Detoxification","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2006-10","conditions":"Alcohol Use Disorder","enrollment":40},{"nctId":"NCT00596531","phase":"PHASE1","title":"Clinical Trial of Acamprosate for Tinnitus","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2008-01","conditions":"Tinnitus","enrollment":154},{"nctId":"NCT00249379","phase":"PHASE4","title":"Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2005-06","conditions":"Alcohol Dependence","enrollment":26},{"nctId":"NCT02361424","phase":"PHASE2","title":"Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)","status":"COMPLETED","sponsor":"Pharnext S.C.A.","startDate":"2013-02","conditions":"Alzheimer Disease","enrollment":47},{"nctId":"NCT02361242","phase":"PHASE2","title":"24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion","status":"COMPLETED","sponsor":"Pharnext S.C.A.","startDate":"2013-06","conditions":"Alzheimer Disease","enrollment":45},{"nctId":"NCT00640952","phase":"NA","title":"Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2006-08","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT00004552","phase":"PHASE2","title":"Acamprosate Treatment: Mechanisms of Action","status":"COMPLETED","sponsor":"Yale University","startDate":"","conditions":"Alcoholism","enrollment":120},{"nctId":"NCT00330174","phase":"PHASE4","title":"Acamprosate in Alcoholics With Comorbid Anxiety or Depression","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2006-04","conditions":"Alcohol Dependence, Major Depression, Social Anxiety Disorder","enrollment":90},{"nctId":"NCT00591565","phase":"NA","title":"An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2006-06","conditions":"Anxiety","enrollment":13},{"nctId":"NCT00662571","phase":"","title":"Acamprosate: Genes Associated With Response","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-05","conditions":"Alcoholism","enrollment":485},{"nctId":"NCT00425711","phase":"NA","title":"Study of Acamprosate in Driving Under the Influence (DUI) Court Participants","status":"TERMINATED","sponsor":"University of Oklahoma","startDate":"2007-02","conditions":"Alcohol Dependence","enrollment":4},{"nctId":"NCT00452543","phase":"PHASE4","title":"Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-03","conditions":"Major Depressive Disorder, Alcohol Abuse, Alcohol Dependence","enrollment":23},{"nctId":"NCT00605904","phase":"PHASE2","title":"Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2008-01","conditions":"Alcoholism","enrollment":37},{"nctId":"NCT00106106","phase":"PHASE2","title":"Acamprosate to Reduce Symptoms of Alcohol Withdrawal","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2005-03","conditions":"Alcohol-Related Disorders, Alcohol Dependence, Alcoholism","enrollment":56},{"nctId":"NCT00511940","phase":"PHASE2, PHASE3","title":"Acamprosate in the Treatment of Binge-Eating Disorder","status":"COMPLETED","sponsor":"Lindner Center of HOPE","startDate":"2007-04","conditions":"Binge Eating Disorder","enrollment":40},{"nctId":"NCT00855699","phase":"PHASE4","title":"Alcohol Detoxification in Primary Care Treatment (ADEPT)","status":"COMPLETED","sponsor":"University of Bristol","startDate":"2009-11","conditions":"Alcoholism","enrollment":36},{"nctId":"NCT00006206","phase":"PHASE3","title":"COMBINE (Acamprosate/Naltrexone)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"1997-08","conditions":"Alcoholism","enrollment":1375},{"nctId":"NCT00330486","phase":"PHASE1, PHASE2","title":"Open Label Trial of Acamprosate in Bipolar Alcoholics","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2006-04","conditions":"Alcohol Dependence, Bipolar Disorder","enrollment":9},{"nctId":"NCT00317031","phase":"PHASE4","title":"Individually Adapted Therapy of Alcoholism","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2002-11","conditions":"Alcoholism","enrollment":435},{"nctId":"NCT00159107","phase":"PHASE4","title":"Integrative Therapy in Alcoholism","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2003-05","conditions":"Alcoholism","enrollment":371},{"nctId":"NCT00435435","phase":"PHASE4","title":"Comparative Trial Of Disulfiram, Naltrexone And Acamprosate In The Treatment Of Alcohol Dependence","status":"COMPLETED","sponsor":"Finnish Institute for Health and Welfare","startDate":"2000-09","conditions":"Alcohol Dependence","enrollment":243},{"nctId":"NCT00120601","phase":"PHASE4","title":"Trial for the Treatment of Alcohol Dependence","status":"UNKNOWN","sponsor":"University of Sydney","startDate":"2003-03","conditions":"Alcoholism","enrollment":200}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DIABETES MELLITUS"},{"count":1,"reaction":"HYPOKALAEMIA"}],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Acamprosate(Campral)","Acamprosate, campral, alcohol dependence medication"],"phase":"marketed","status":"active","brandName":"acamprosate (Campral)","genericName":"acamprosate (Campral)","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acamprosate modulates glutamate and GABA neurotransmission to restore neurochemical balance disrupted by chronic alcohol use. Used for Maintenance of abstinence in alcohol-dependent patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}